Loading...
NPI 1609273317 · Brookhaven, GA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Lifebrite Laboratories, LLC is a clinical medical laboratory provider located in Brookhaven, Georgia. This profile covers 36 Medicare and 105 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Lifebrite Laboratories, LLC |
| Address | 9 Corporate Blvd Ne |
| City | Brookhaven |
| State | GA |
| ZIP | 30329 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | November 24, 2014 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $9.4M |
| Medicare | $526K |
Payer mix is heavily Medicaid-weighted: this provider reported $526K in total Medicare revenue and $9.4M in total Medicaid revenue, so Medicaid dominates the revenue base and Medicare represents only a small fraction of lifetime billing. That imbalance implies revenue sensitivity to Medicaid contracting and utilization trends rather than to the Medicare market.
Medicare revenue is highly concentrated in toxicology codes: the top three Medicare codes account for 90.0% of this provider's Medicare revenue, led by G0483 (1.6K claims, $242 avg paid/claim, $394.7K revenue, 75.5% of this provider's total Medicare revenue), followed by G0482 (217 claims, $195 avg paid/claim, $42.3K revenue, 8.1%) and 80307 (551 claims, $61 avg paid/claim, $33.6K revenue, 6.4%). This mix signals that Medicare billing is driven almost entirely by definitive and presumptive drug testing rather than broad clinical panels.
Medicaid billing also concentrates on a narrow toxicology and molecular testing set: the top three Medicaid codes account for 62.3% of Medicaid revenue, with G0483 at $2.2M (39.2K claims, $57 avg paid/claim, 24.9%), 80307 at $1.7M (49.7K claims, $35 avg paid/claim, 19.3%), and G0482 at $1.6M (17.9K claims, $91 avg paid/claim, 18.1%). In addition, high-throughput SARS-CoV-2 testing (U0003, 16.8K claims, $70 avg paid/claim, $1.2M, 13.1%) is a material secondary revenue stream for Medicaid.
Competitive standing differs sharply by payer: for Medicare the single largest code G0483 ranks #64 of 1063 providers nationally (94th percentile) and is annotated as "typical, unremarkable volume for this code," while G0482 ranks #421 of 1618 (74th percentile) and 80307 ranks #642 of 4760 (87th percentile). These placements indicate the provider is a recognizable but not dominant national participant on Medicare toxicology codes, with a single high-contribution code driving most Medicare revenue.
By contrast, the provider is a major, and in some tests dominant, in-state Medicaid player: G0483 ranks #1 of 29 providers in-state (100th percentile; extreme outlier, far above typical state volume), 80307 ranks #4 of 68 (96th percentile; typical, unremarkable volume), and G0482 ranks #5 of 26 (84th percentile; typical, unremarkable volume). Multiple therapeutic drug monitoring and mass-spec codes (for example 82542, 80184, 80159, 80173, 80162) are reported as ranking #1 in-state (100th percentile or "notably above typical state volume" for some codes), indicating clear state-level concentration and operational scale in targeted assays.
Service-line implications: the dominant codes are definitive drug tests using GC/MS or LC/MS techniques (G0483, G0482) plus presumptive screens (80307) and numerous therapeutic drug monitoring assays, which together imply a centralized reference-lab model focused on high-volume toxicology, mass-spectrometry assays, and some infectious-disease molecular testing. Claim volumes such as 39.2K claims for Medicaid G0483 and 49.7K claims for Medicaid 80307 support the characterization of high-throughput operations rather than low-volume clinical outreach.
Revenue concentration creates both market strength and dependency: with the top three Medicare codes representing 90.0% of Medicare revenue and the top three Medicaid codes representing 62.3% of Medicaid revenue, the business is highly dependent on a small set of tests (chiefly drug testing and a few molecular assays). That pattern gives the lab market leverage in those test types—especially in-state for G0483 where it is an "extreme outlier"—but also exposes the organization to reimbursement or utilization shifts affecting a narrow code set.
Operational tenure is established: the NPI was enumerated on 2014-11-24 (~12 years ago), indicating several years in-market during which the provider has built the concentrated toxicology and molecular testing volumes reflected in the Medicaid and Medicare billing patterns. This multi-year presence aligns with the scale and in-state ranking shown across the reported codes.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
36 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,630 | $240 | $394.7K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 220 | $200 | $42.3K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 550 | $60 | $33.6K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 200 | $150 | $29.8K |
| 87900 | The lab analyst measures a patient’s susceptibility or resistance to drugs aimed at a virus. The test predicts the behavior of the phenotype based on comparing patient data to regularly updated… | 20 | $130 | $2.9K |
| 83970 | Parathyroid hormone test measures the level of PTH in the blood. This test is done to ascertain the level of calcium and evaluate the parathyroid function. | 40 | $40 | $1.8K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 120 | $10 | $1.5K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 10 | $100 | $1.4K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 90 | $20 | $1.4K |
| 82670 | The lab analyst measures the level of total estradiol, an estrogenic hormone, on a specimen such as blood using a method such as liquid chromatography–tandem mass spectrometry (LC–MS/MS) to evaluate… | 40 | $30 | $1.2K |
Showing 1–10 of 36
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 36 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
36 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| G0483 | 3 | 60 | 120 | $240 | $99.9K |
| G0480 | 104 | 110 | 90 | $110 | $48.1K |
| G0482 | 19 | 80 | 70 | $190 | $36.8K |
| G0481 | 18 | 120 | 80 | $150 | $36.5K |
| 80307 | 42 | 210 | 210 | $60 | $28.5K |
| 84681 | 4 | 10 | 160 | $20 | $23.7K |
| 82670 | 7 | 10 | 50 | $30 | $18.1K |
| 83970 | 63 | 130 | 40 | $40 | $15.2K |
| 83525 | 5 | 10 | 70 | $10 | $11.3K |
| 80164 | 8 | 10 | 140 | $10 | $10.9K |
Showing 1–10 of 36
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
105 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 39,230 | $60 | $2.2M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 49,660 | $40 | $1.7M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 17,900 | $90 | $1.6M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 16,840 | $70 | $1.2M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 15,930 | $30 | $541.6K |
| 82542 | The lab analyst performs the technical lab test to evaluate the specimen for the presence or amount of a nondrug analyte by using column chromatography and possibly mass spectrometry. | 17,480 | $20 | $314.6K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 10,300 | $20 | $216.4K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 4,580 | $40 | $196.8K |
| 80184 | The lab analyst performs the technical lab test to analyze a specimen to quantitate the amount of phenobarbital present, which is an anticonvulsant medication. | 6,750 | $20 | $101.2K |
| 80159 | A lab tests a patient's specimen to determine the level of clozapine. | 5,770 | $20 | $98.1K |
Showing 1–10 of 105
How this provider's Medicaid billing volume and revenue compare to other Georgia providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Georgia median
105 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 5 | 40 | 850 | $70 | $983K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 30 | 2,370 | $100 | $757.4K |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 5 | 10 | 140 | $20 | $529.9K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 5 | 30 | 860 | $70 | $525.3K |
| 81408 | The lab analyst performs the technical lab test to complete one of the specific genetic analyses listed in this Tier 2, Level 9 molecular pathology code. | 10 | 10 | 480 | $520 | $503.7K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 9 | 30 | 940 | $30 | $467.9K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 4 | 70 | 2,840 | $30 | $428.7K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 4 | 30 | 1,130 | $50 | $338.3K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 13 | 20 | 430 | $90 | $241.3K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 12 | 40 | 180 | $20 | $194.3K |
Showing 1–10 of 105
Other providers in the same ZIP code as Lifebrite Laboratories, LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.